The reduction of cardiovascular events is not only related to anti-diabetic properties, but also to pleotropic effects leading to the reduction of the residual cardiovascular risk, that has been defined as the risk of progression of CV events (MACE or HF) that remains after the optimal glycaemic control in T2DM patients, and it seems to be related to meta-inflammation, defined as a low-grade chronic and sterile inflammatory status
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
doi: 10.1016/j.ejphar.2004.02.055 [DOI] [PubMed] [Google Scholar] 134.Chabot C, Massicotte G, Milot M, Trudeau F, Gagn J
The dose reduction approach This method involves stepping down through progressively lower doses before stopping entirely
This is of particular, but not exclusive relevance, to statins, calcium channel blockers, digoxin and the blood sugar drug, metformin